July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Preliminary refractive results of the Clareon® Intraocular Lens (IOL): about 150 cases
Author Affiliations & Notes
  • Mayeul Chaperon
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Hussam El Chehab
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • ANTOINE LEVRON
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Roman Chudzinski
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Emilie Agard
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Corinne Dot
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Footnotes
    Commercial Relationships   Mayeul Chaperon, None; Hussam El Chehab, None; ANTOINE LEVRON, None; Roman Chudzinski, None; Emilie Agard, None; Corinne Dot, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3712. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mayeul Chaperon, Hussam El Chehab, ANTOINE LEVRON, Roman Chudzinski, Emilie Agard, Corinne Dot; Preliminary refractive results of the Clareon® Intraocular Lens (IOL): about 150 cases. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3712.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cataract surgery is the most common surgical procedure performed in France with nearly one million of surgeries per year. Clareon® is a new monofocal hydrophobic acrylic IOL recently marketed in Europe in May 2018 and developed by Alcon company. The objective of our study is to analyze the preliminary refractive results of the Clareon® IOLs in order to evaluate the A constant used in the different IOL calculation formulas.

Methods : We conducted a retrospective, monocentric study on IOLs implanted consecutively between July 2017 and October 2018 by a single surgeon. The power was evaluated by using the IOL Master 700® (Zeiss) for emmetropia with the SRK/T formula except for hyperopic patients where the multiformula function was preferred. The preoperative A constant used was 119.1, as recommended by Alcon. The surgical procedure associated 1 main incision of 2.2 mm at 120° and 2 side ports of 1 mm 90° apart. The postoperative refraction selected for the study was performed 1 month after surgery.

Results : 150 eyes were implanted between July 2017 and October 2018. The average age of the patients was 74 years, the mean axial length was 23.86 mm (21.67-28.37), the mean anterior chamber depth was 3.16 mm (2.07-4.34). The mean uncorrected visual acuity (UCVA) was 0,89, the median was 0,925. Almost half of the patients (47%) had an UCVA superior to 10/10 and ¾ (73%) superior to 0,8. The mean post-operative sphere was +0.41D +/- 0.3, the median was +0.125D. The optimized A constant was thus evaluated as 119.3. No YAG capsulotomy was performed during the first year. Analysis of the transparency of Clareon® did not reveal any significant glistering (grade 0) for 100% of patients.

Conclusions : Although the refractive results are excellent, the Clareon® IOL requires a slight optimization of its A constant near 119.3 in our study. This should be confirmed by ULIB soon. The tolerance during the first year is excellent as well as the transparency of this new IOL.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×